Suppr超能文献

韩国大邱市 2019 年冠状病毒病中度至重度感染合并糖尿病患者的临床特征和结局。

The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea.

机构信息

Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.

Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.

出版信息

Diabetes Metab J. 2020 Aug;44(4):602-613. doi: 10.4093/dmj.2020.0146. Epub 2020 Aug 12.

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) is a global pandemic that had affected more than eight million people worldwide by June 2020. Given the importance of the presence of diabetes mellitus (DM) for host immunity, we retrospectively evaluated the clinical characteristics and outcomes of moderate-to-severe COVID-19 in patients with diabetes.

METHODS

We conducted a multi-center observational study of 1,082 adult inpatients (aged ≥18 years) who were admitted to one of five university hospitals in Daegu because of the severity of their COVID-19-related disease. The demographic, laboratory, and radiologic findings, and the mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM. In addition, 1:1 propensity score (PS)-matching was conducted with the DM group.

RESULTS

Compared with the non-DM group (=847), patients with DM (=235) were older, exhibited higher mortality, and required more intensive care. Even after PS-matching, patients with DM exhibited more severe disease, and DM remained a prognostic factor for higher mortality (hazard ratio, 2.40; 95% confidence interval, 1.38 to 4.15). Subgroup analysis revealed that the presence of DM was associated with higher mortality, especially in older people (≥70 years old). Prior use of a dipeptidyl peptidase-4 inhibitor or a renin-angiotensin system inhibitor did not affect mortality or the clinical severity of the disease.

CONCLUSION

DM is a significant risk factor for COVID-19 severity and mortality. Our findings imply that COVID-19 patients with DM, especially if elderly, require special attention and prompt intensive care.

摘要

背景

2019 年冠状病毒病(COVID-19)是一场全球性大流行疾病,截至 2020 年 6 月,已在全球范围内影响了超过 800 万人。鉴于糖尿病(DM)对宿主免疫的重要性,我们回顾性评估了伴有糖尿病的中重度 COVID-19 患者的临床特征和结局。

方法

我们对 5 家位于大邱的大学医院因 COVID-19 相关疾病严重程度而住院的 1082 例成年住院患者(年龄≥18 岁)进行了一项多中心观察性研究。比较了 DM 组和非 DM 组(n=847)患者的人口统计学、实验室和影像学结果,以及死亡率、严重疾病的发生率和隔离时间。此外,DM 组还进行了 1:1 倾向评分(PS)匹配。

结果

与非 DM 组(n=847)相比,DM 组(n=235)患者年龄较大,死亡率较高,需要更强化的护理。即使进行 PS 匹配后,DM 组患者的疾病严重程度更高,DM 仍然是死亡率较高的预后因素(风险比,2.40;95%置信区间,1.38 至 4.15)。亚组分析显示,DM 的存在与更高的死亡率相关,尤其是在老年人(≥70 岁)中。二肽基肽酶-4 抑制剂或肾素-血管紧张素系统抑制剂的既往使用并未影响死亡率或疾病的临床严重程度。

结论

DM 是 COVID-19 严重程度和死亡率的重要危险因素。我们的研究结果表明,COVID-19 合并 DM 的患者,尤其是老年人,需要特别关注并及时进行强化护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d77d/7453989/d643bc796ed3/dmj-44-602-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验